Anti-HHV-8 LNA-1 [LN53]

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

• Name: Anti-HHV-8 LNA-1 [LN53]
• Alternate name: ORF-73 of human herpesvirus 8 or HHV-8 positive cells
• Cancer: Blood cancer;Skin cancer
• Cancers detailed: Kaposi's Sarcoma;Primary Effusion Lymphoma
• Research fields: Microbiology
• Clone: LN53
• Tool sub type: Primary antibody
• Class: Monoclonal
• Conjugation: Unconjugated
• Reactivity: Virus
• Host: Rat
• Application: ELISA ; FACS ; IHC ; IP ; WB
• Description: Rat monoclonal antibody which targets human KSHV/HHV8 and simian RFHV Orf73 latency-associated nuclear antigen (LANA or LNA) with high specificity. Background and Research Application Human herpesvirus-8 (HHV-8, also called KSHV) has been found to be associated with three different diseases observed in AIDS patients; Kaposi's sarcoma (KS), primary effusion lymphoma ( PEL, a rare type of non-Hodgkin lymphoma affecting the body cavities) and multicentric Castleman's disease (MCD). To date there is much evidence to support a direct role for HHV-8 in KS. In early KS, HHV-8 is present in 90% of spindle cells, but not in normal vascular endothelium. HHV-8 encodes a latent nuclear antigen (LNA-1) which is the product of the viral gene Orf73. This is the target of anti-HHV-8 LNA-1. Anti-HHV-8 LNA-1 recognizes an EQEQE repeat epitope in Orf73 and reacts with antigens in paraffin-embedded tissue. LNA-1 is a nuclear protein which functions to ensure the maintenance of the viral genome by tethering the viral episomal DNA to host cell chromosomes. LNA-1 also regulates the cellular transcription program via interaction with a number of cellular proteins. These include transcriptional regulators and known tumour suppressors, p53 and retinoblastoma (RB). This nuclear protein is also involved in maintaining the latent state of the virus by inhibiting viral replication. LNA-1 is recognized by most infected patient sera and is the basis of current immunofluorescence assays used in epidemiological studies of HHV-8 infection. Orf73 encodes the major immunogenic LNA-1, identified as a nuclear stippling pattern in cells when exposed to sera of patients with KS.
• Immunogen: Recombinant protein corresponding to the latent nuclear antigen-1 molecule of HHV-8
• Immunogen uniprot id: Q9QR71
• Isotype: IgG2c

Target Details

• Target: Latent nuclear antigen 1 (LNA-1; ORF73) of HHV-8
• Target background: Rat monoclonal antibody which targets human KSHV/HHV8 and simian RFHV Orf73 latency-associated nuclear antigen (LANA or LNA) with high specificity. Background and Research Application Human herpesvirus-8 (HHV-8, also called KSHV) has been found to be associated with three different diseases observed in AIDS patients; Kaposi's sarcoma (KS), primary effusion lymphoma ( PEL, a rare type of non-Hodgkin lymphoma affecting the body cavities) and multicentric Castleman's disease (MCD). To date there is much evidence to support a direct role for HHV-8 in KS. In early KS, HHV-8 is present in 90% of spindle cells, but not in normal vascular endothelium. HHV-8 encodes a latent nuclear antigen (LNA-1) which is the product of the viral gene Orf73. This is the target of anti-HHV-8 LNA-1. Anti-HHV-8 LNA-1 recognizes an EQEQE repeat epitope in Orf73 and reacts with antigens in paraffin-embedded tissue. LNA-1 is a nuclear protein which functions to ensure the maintenance of the viral genome by tethering the viral episomal DNA to host cell chromosomes. LNA-1 also regulates the cellular transcription program via interaction with a number of cellular proteins. These include transcriptional regulators and known tumour suppressors, p53 and retinoblastoma (RB). This nuclear protein is also involved in maintaining the latent state of the virus by inhibiting viral replication. LNA-1 is recognized by most infected patient sera and is the basis of current immunofluorescence assays used in epidemiological studies of HHV-8 infection. Orf73 encodes the major immunogenic LNA-1, identified as a nuclear stippling pattern in cells when exposed to sera of patients with KS.

Applications

• Application: ELISA ; FACS ; IHC ; IP ; WB

Handling

• Format: Liquid
• Concentration: 1 mg/ml
• Unit size: 100 ug
• Storage buffer: PBS with 0.02% azide
• Storage conditions: -15° C to -25° C
• Shipping conditions: Shipping at 4° C

References

• Juillard et al. 2019. J Virol. 93(6):. PMID: 30626680.
• Pires de Miranda et al. 2018. J Virol. 92(21):. PMID: 30111565.
• Grant et al. 2018. Proc Natl Acad Sci U S A. 115(19):4992-4997. PMID: 29610353.
• Garrigues et al. 2017. J Virol. 91(24):. PMID: 28978712.
• Bruce et al. 2017. Pathogens. 6(1):. PMID: 28335496.
• Brouchet et al. 2005. Br J Cancer. 92(4):743-6. PMID: 15700034.
• Detection of oncogenic virus genomes and gene products in lung carcinoma.
• Caussinus et al. 2001. J Clin Pathol. 54(10):790-1. PMID: 11577129.
• Simultaneous occurrence of Epstein-Barr virus associated Hodgkin's disease and HHV-8 related multicentric Castleman's disease: a fortuitous event?
• Gomez-Brouchet et al. 2001. J Clin Pathol. 54(8):617-8. PMID: 11477117.
• Immunohistochemical assessment of human herpesvirus 8 infection in primary central nervous system large B cell lymphomas.
• Kellam et al. 1999. J Virol. 73(6):5149-55. PMID: 10233979.
• Characterization of monoclonal antibodies raised against the latent nuclear antigen of human herpesvirus 8.
• Dupin et al. 1999. Proc Natl Acad Sci U S A. 96(8):4546-51. PMID: 10200299.
• Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma.